Efficacy and safety of irreversible electroporation for malignant liver tumors: a systematic review and meta-analysis
- 27 February 2021
- journal article
- review article
- Published by Springer Science and Business Media LLC in European Radiology
- Vol. 31 (9), 6511-6521
- https://doi.org/10.1007/s00330-021-07742-y
Abstract
Objective The data regarding overall survival (OS) and progression-free survival (PFS) following irreversible electroporation (IRE) is scarce. We performed a systematic review of the safety and efficacy of IRE for liver malignancies. Methods Searches of MEDLINE, EMBASE, and SCOPUS databases were performed through September 1, 2019. Studies reporting the survival data (OS and PFS) and complications (graded according to the Society of interventional Radiology classification) were included. A generalized linear mixed method with a random-effects model was used for assessing pooled incidence rates and corresponding 95% confidence intervals (CIs). Results A total of 25 studies (n = 776, 15 prospective, 10 retrospective) were included. Metastasis, hepatocellular carcinoma, and cholangiocarcinoma were present in 354, 285, and 100 patients, respectively. The pooled OS at 6, 12, 24, and 36 months was 93.28% (95% CI: 63.23–99.12, I2= 67%), 81.29% (95% CI: 69.80–89.22, I2 = 73%), 61.47% (95% CI: 52.81–69.46, I2 = 0%), and 40.88% (95% CI: 28.43–54.61, I2 = 64%), respectively. The pooled PFS at 6, 12, and 24 months was 79.72% (95% CI: 67.88–87.97, I2 = 70%), 64.19% (95% CI: 56.68–71.06, I2 = 57%), 49.05% (95% CI: 11.47–87.73, I2 = 96%), respectively. Overall complication rate was 23.7%. Major complications (grade C-F) occurred in 6.9% patients. Conclusion IRE is associated with favorable OS and PFS. Although the overall complication rate is high, most complications are graded as minor. Key Points • The pooled OS and PFS at 6, 12, and 24 months for all the tumor types was 93.28% and 79.72%, 81.29% and 64.19%, and 61.47% and 49.05%, respectively. • HCC was associated with a better OS at 12 and 36 months. • The overall complication rate was 23.7%, with major complications (SIR grade C-F) comprising 6.9%.This publication has 45 references indexed in Scilit:
- Irreversible Electroporation for Nonthermal Tumor Ablation in the Clinical Setting: A Systematic Review of Safety and EfficacyJournal of Vascular and Interventional Radiology, 2014
- Local Control of Perivascular Malignant Liver Lesions Using Percutaneous Irreversible Electroporation: Initial ExperiencesCardioVascular and Interventional Radiology, 2014
- Irreversible Electroporation Ablation (IRE) of Unresectable Soft Tissue Tumors: Learning Curve Evaluation in the First 150 Patients TreatedPLOS ONE, 2013
- Irreversible Electroporation for the Ablation of Liver TumorsArchives of Surgery, 2012
- Safety and early efficacy of irreversible electroporation for hepatic tumors in proximity to vital structuresJournal of Surgical Oncology, 2012
- Ablation of Perivascular Hepatic Malignant Tumors with Irreversible ElectroporationJournal of the American College of Surgeons, 2012
- Stereotactic radiosurgery for glioblastoma: retrospective analysisRadiation Oncology, 2009
- Tissue Ablation with Irreversible ElectroporationAnnals of Biomedical Engineering, 2005
- Treatment of Focal Liver Tumors with Percutaneous Radio-frequency Ablation: Complications Encountered in a Multicenter StudyRadiology, 2003
- Metabolism of ethylmalic acids by Pseudomonas aeruginosaBiochemistry, 1968